CDP-choline does not inhibit erythrocyte glycolytic or pentose phosphate pathway enzyme activity.
An increased concentration of cytidine diphosphocholine (CDP-choline) has been observed in erythrocytes in the hemolytic anemia due to hereditary pyrimidine 5'-nucleotidase deficiency (P5Nase, EC 3.1.3.5) and in a patient with a chronic hemolytic anemia not due to P5Nase deficiency, as reported by Paglia and co-workers in 1983. In the current studies, we were unable to demosntrate a significant inhibitory effect of 4 mmol/l CDP-choline on the activities of the enzymes of the Embden-Meyerhof and pentose phosphate pathways. The physiologic significance of increased erythrocytic CDP-choline remains to be determined.
D002794:Choline / Q000031:analogs & derivatives*; D003566:Cytidine Diphosphate Choline / Q000494:pharmacology*; D004798:Enzymes / Q000097:blood; D004912:Erythrocytes / Q000187:drug effects* / Q000201:enzymology; D006019:Glycolysis / Q000187:drug effects*; D006801:Humans; D010427:Pentose Phosphate Pathway / Q000187:drug effects*
D004798:Enzymes; D003566:Cytidine Diphosphate Choline; D002794:Choline